Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.48 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7009713 | 0.82 | MEN1 (0.58) | KCNH2GAALMNAMEN1KMT2A | |
| SCHEMBL7009709 | 0.82 | MEN1 (0.58) | KCNH2GAALMNAMEN1KMT2A | |
| SCHEMBL1993401 | 0.82 | KCNH2 (0.47) | TSHRKCNH2GAAALDH1A1 | |
| SCHEMBL6618592 | 0.82 | MEN1 (0.48) | TSHRKCNH2CRHBPCRHR2LMNA | |
| SCHEMBL6618598 | 0.82 | MEN1 (0.48) | TSHRKCNH2CRHBPCRHR2LMNA | |
| SCHEMBL20380500 | 0.82 | CRHBP (0.59) | TSHRKCNH2CRHBPCRHR2LMNA | |
| SCHEMBL29254204 | 0.78 | CRHBP (0.46) | TSHRCRHBPCRHR2GAALMNA | |
| SCHEMBL29254207 | 0.78 | CRHBP (0.46) | TSHRCRHBPCRHR2GAALMNA | |
| SCHEMBL14894125 | 0.77 | KCNH2 (0.51) | TSHRKCNH2CRHBPCRHR2MEN1 | |
| SCHEMBL16107476 | 0.76 | ALDH1A1 (0.51) | TSHRKCNH2CRHBPCRHR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697636-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN LA ROCHE (US) | 2021-03-04 | — | — | US | disclosed |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2020-02-13 | — | — | US | disclosed |
| EP-3187490-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2017-07-05 | — | — | EP | disclosed |
| US-9452980-B2 | Substituted benzamides | HOFFMANN-LA ROCHE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | HOFFMANN-LA ROCHE INC. | 2016-09-15 | — | — | US | disclosed |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264596-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | TSHR 15/4885KCNH2 557/4885CRHBP 1719/4885 |
| US-20210061760-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | TSHR 15/4885KCNH2 557/4885CRHBP 1719/4885 |
| US-20110152245-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | TSHR 15/4885KCNH2 557/4885CRHBP 1719/4885 |
| US-20200048194-A1 | SUBSTITUTED BENZAMIDES | TAAR1, TAAR5, NPY1R | TSHR 15/4885KCNH2 557/4885CRHBP 1719/4885 |
| US-11697636-B2 | Substituted benzamides | TAAR1, TAAR5, NPY1R | TSHR 15/4885KCNH2 557/4885CRHBP 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.